Medical device maker GE Healthcare is working with advisers to explore options including the sale of a stake in its China unit, Bloomberg News reported on Thursday, citing people familiar with the matter.
GE HealthCare (GEHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
GE HealthCare Technologies Inc. (NASDAQ:GEHC ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:45 AM EDT Company Participants James Saccaro - VP & CFO Carolynne Borders - Chief Investor Relations Officer Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst Good morning. I'm Larry Biegelsen, the medical device analyst at Wells Fargo.
Investors interested in stocks from the Medical - Products sector have probably already heard of GE HealthCare Technologies (GEHC) and Agilent Technologies (A). But which of these two stocks is more attractive to value investors?
GE HealthCare's Vivid Pioneer, cleared by CE Mark and FDA, brings AI-powered speed, precision and efficiency to cardiac imaging.
GE HealthCare's Q2 results highlight revenue growth, AI-driven innovation, and global expansion with margin gains and strong demand.
Investors looking for stocks in the Medical - Products sector might want to consider either GE HealthCare Technologies (GEHC) or Agilent Technologies (A). But which of these two stocks offers value investors a better bang for their buck right now?
GE HealthCare (GEHC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?
GE HealthCare Technologies delivered strong Q2 results, beating revenue and earnings expectations, and raised full-year guidance despite a sharp share price drop. The company is trading at a significant discount to peers, offering substantial upside potential even at the low end of industry valuation multiples. Management is actively mitigating tariff impacts, investing in innovation, and launching new products to drive future growth and operational efficiency.
GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.
While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.